- Home
- INKT vs IFRX Comparison
INKT vs IFRX Comparison
Compare INKT & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- IFRX
- Stock Information
- Founded
- INKT 2017
- IFRX 2007
- Country
- INKT United States
- IFRX Germany
- Employees
- INKT N/A
- IFRX N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- INKT Health Care
- IFRX Health Care
- Exchange
- INKT Nasdaq
- IFRX Nasdaq
- Market Cap
- INKT 48.7M
- IFRX 53.5M
- IPO Year
- INKT 2021
- IFRX 2017
- Fundamental
- Price
- INKT $14.91
- IFRX $0.86
- Analyst Decision
- INKT Buy
- IFRX Strong Buy
- Analyst Count
- INKT 3
- IFRX 4
- Target Price
- INKT $37.50
- IFRX $7.75
- AVG Volume (30 Days)
- INKT 201.7K
- IFRX 210.6K
- Earning Date
- INKT 08-14-2025
- IFRX 08-07-2025
- Dividend Yield
- INKT N/A
- IFRX N/A
- EPS Growth
- INKT N/A
- IFRX N/A
- EPS
- INKT N/A
- IFRX N/A
- Revenue
- INKT N/A
- IFRX $191,224.00
- Revenue This Year
- INKT N/A
- IFRX N/A
- Revenue Next Year
- INKT N/A
- IFRX $1,276.37
- P/E Ratio
- INKT N/A
- IFRX N/A
- Revenue Growth
- INKT N/A
- IFRX 54.36
- 52 Week Low
- INKT $4.56
- IFRX $0.71
- 52 Week High
- INKT $76.00
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- INKT 49.04
- IFRX 50.72
- Support Level
- INKT $13.10
- IFRX $0.78
- Resistance Level
- INKT $18.00
- IFRX $0.86
- Average True Range (ATR)
- INKT 2.10
- IFRX 0.07
- MACD
- INKT -0.26
- IFRX 0.00
- Stochastic Oscillator
- INKT 44.28
- IFRX 58.33
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.